We report a unique case of therapy-induced TLS in a patient newly diagnosed with CLL, following the initiation of acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. Here, BTK is linked to B-cell chronic lymphocytic leukemia.